Page last updated: 2024-11-06

crisnatol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

crisnatol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57062
CHEMBL ID61495
SCHEMBL ID15990
MeSH IDM0159027

Synonyms (20)

Synonym
crisnatol
CHEMBL61495
crisnatolum [latin]
2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol
crisnatol [inn]
bw a770u
crisnatolum
96389-68-3
2j71ur51ue ,
1,3-propanediol, 2-((6-chrysenylmethyl)amino)-2-methyl-
unii-2j71ur51ue
2-((6-chrysenylmethyl)amino)-2-methyl-1,3-propanediol
SCHEMBL15990
2-(6-chrysenylmethylamino)-2-methylpropane-1,3diol
SBRXTSOCZITGQG-UHFFFAOYSA-N
DTXSID10242217
Q18559330
MS-25306
CS-0619908
HY-108999A

Research Excerpts

Overview

Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol. Crisnatol has shown promise as an antitumor agent in preclinical testing.

ExcerptReferenceRelevance
"Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. "( Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.
Cobb, PW; Craig, JB; Harman, GS; Havlin, KA; Koeller, J; Kuhn, JG; Luther, JS; Turner, JN; Tweedy, DA; Weiss, GR, 1991
)
2.04
"Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity. "( Crisnatol mesylate: phase I dose escalation by extending infusion duration.
Baker, LH; Chabot, GG; Lucas, S; Poplin, EA; Tuttle, RL; Wargin, WA, 1991
)
3.17
"Crisnatol is a novel lipophilic arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and human tumor models which functions as a DNA intercalator. "( Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
Craig, JB; Harman, GS; Koeller, J; Kuhn, JG; Lucas, VS; Luther, JS; Turner, JN; Tuttle, RL; Tweedy, DA; Weiss, GR, 1988
)
1.98

Pharmacokinetics

ExcerptReferenceRelevance
"A microtiter pharmacodynamic assay is described that evaluates antitumor activity in vitro within a matrix of extracellular drug concentrations (C) and exposure times (T)."( In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.
Adams, DJ, 1989
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID142446Antitumor activity in murine lymphocytic leukemia P388 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
AID135484Number of animals survived after 60 days; 3/61991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
AID132190Percent increase in life span (% ILS) was tested at optimal dose.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
AID135482Number of animals survived after 30 days; 6/81991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
AID142444Lethal dose in murine lymphocytic leukemia P388 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (16.67)18.7374
1990's10 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (38.46%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (53.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]